lantheus.com (LNTH): Rasio P/E diaturake wutah

Simbol lan logo merek lantheus.com (LNTH)

Lantheus Holdings, Inc. (LNTH) is implementing advanced AI diagnostic methods and building on the success of Pylarify in oncology. The PEG ratio clearly demonstrates the asset's investment attractiveness, with the latest value recorded as 1.21. US-based cardiology drug manufacturing plants ensure business stability. The high margins of radiopharmaceuticals, coupled with expanding shipments, create powerful operating leverage by optimizing laboratory costs.

LNTH - Pangali PEG Lantheus Holdings ing rentang 04.07.2022 - 16.11.2026

lantheus.com (LNTH) - rincian metrik lan laporan keuangan

- nilai saham lan prakiraan konsensus rega:
Analisis fundamental perusahaan:LNTH, Lantheus Holdings, Inc.
Produk seri Lantheus Holdings, Inc.

Finding a balance between operational risks and return on equity within the radiopharmaceutical sector requires an analysis of the expansion rates of Lantheus Holdings, Inc. (LNTH) in the oncology diagnostics market. The peg_co multiple compares the current P/E to earnings growth, where a value below one confirms the business is undervalued, given the company's technological leadership and its sustained dominance in cancer imaging.